Eurofins-Cerep (XPAR:ALECR) Piotroski F-Score: 5 (As of Jul. 27, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALECR Eurofins-Cerep SA XPAR:ALECR
27 GF Score
Price €16,300.00
GF Value €20,317.48
! 4 Warning Signs
View Full Analysis

What is Eurofins-Cerep Piotroski F-Score?

Eurofins-Cerep XPAR:ALECR 27 Piotroski F-Score is 5 as of Jul. 27, 2026, which is at its 10-year median of 5.00. GuruFocus rates XPAR:ALECR with a GF Score™ of 27/100 and a GF Value™ of €20,317.48. The stock has 4 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, Eurofins-Cerep ranks better than 63.94% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Eurofins-Cerep has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Eurofins-Cerep's Piotroski F-Score or its related term are showing as below:

XPAR:ALECR' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 9
Current: 5

During the past 13 years, the highest Piotroski F-Score of Eurofins-Cerep was 9. The lowest was 3. And the median was 5.

Eurofins-Cerep  (XPAR:ALECR) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Eurofins-Cerep Piotroski F-Score Related Terms


Eurofins-Cerep Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Eurofins-Cerep's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eurofins-Cerep Piotroski F-Score Chart

Eurofins-Cerep Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 4.00 4.00 4.00 5.00

Eurofins-Cerep Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 0.00 4.00 0.00 5.00

XPAR:ALECR vs TMO, DHR, IDXX: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Eurofins-Cerep's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eurofins-Cerep Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins-Cerep's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Eurofins-Cerep's Piotroski F-Score falls into.


XPAR:ALECR
27GF Score
Eurofins-Cerep SA XPAR:ALECR
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was €4.78 Mil.
Cash Flow from Operations was €0.00 Mil.
Revenue was €40.98 Mil.
Gross Profit was €21.92 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (84.063 + 89.02) / 2 = €86.5415 Mil.
Total Assets at the begining of this year (Dec24) was €84.06 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Total Current Assets was €79.41 Mil.
Total Current Liabilities was €10.14 Mil.
Net Income was €7.16 Mil.

Revenue was €40.46 Mil.
Gross Profit was €17.45 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (79.249 + 84.063) / 2 = €81.656 Mil.
Total Assets at the begining of last year (Dec23) was €79.25 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Total Current Assets was €72.65 Mil.
Total Current Liabilities was €10.47 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Eurofins-Cerep's current Net Income (TTM) was 4.78. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Eurofins-Cerep's current Cash Flow from Operations (TTM) was 0.00. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=4.782/84.063
=0.05688591

ROA (Last Year)=Net Income/Total Assets (Dec23)
=7.155/79.249
=0.09028505

Eurofins-Cerep's return on assets of this year was 0.05688591. Eurofins-Cerep's return on assets of last year was 0.09028505. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Eurofins-Cerep's current Net Income (TTM) was 4.78. Eurofins-Cerep's current Cash Flow from Operations (TTM) was 0.00. ==> 0.00 <= 4.78 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=0/86.5415
=0

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=0/81.656
=0

Eurofins-Cerep's gearing of this year was 0. Eurofins-Cerep's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=79.412/10.14
=7.83155819

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=72.651/10.467
=6.94095729

Eurofins-Cerep's current ratio of this year was 7.83155819. Eurofins-Cerep's current ratio of last year was 6.94095729. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Eurofins-Cerep's number of shares in issue this year was 0.005. Eurofins-Cerep's number of shares in issue last year was 0.005. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=21.919/40.975
=0.53493594

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=17.454/40.457
=0.43142101

Eurofins-Cerep's gross margin of this year was 0.53493594. Eurofins-Cerep's gross margin of last year was 0.43142101. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=40.975/84.063
=0.48743205

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=40.457/79.249
=0.51050486

Eurofins-Cerep's asset turnover of this year was 0.48743205. Eurofins-Cerep's asset turnover of last year was 0.51050486. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+0+0+1+1+1+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Eurofins-Cerep has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Eurofins-Cerep (XPAR:ALECR) has a Piotroski F-Score of 5 as of Jul. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Eurofins-Cerep and its competitors. This is near median its historical median of 5.00. Over the past decade, Eurofins-Cerep's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, Eurofins-Cerep ranks #75 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 36.1%.
Is Eurofins-Cerep's Piotroski F-Score too high?
Eurofins-Cerep's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Eurofins-Cerep's value of 5 is 0% at this industry median. Based on the distribution chart, Eurofins-Cerep ranks #75 out of 208 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Eurofins-Cerep has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Eurofins-Cerep's Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins-Cerep ranks #75 out of 208 companies for Piotroski F-Score. This puts Eurofins-Cerep in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Eurofins-Cerep's value of 5 is 0% at this benchmark. Historically, Eurofins-Cerep's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Eurofins-Cerep has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins-Cerep's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Eurofins-Cerep and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins-Cerep's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins-Cerep stock overvalued right now?
Eurofins-Cerep (XPAR:ALECR) has a current Piotroski F-Score of 5. The stock's GF Value™ is €20,317.48, compared to a current price of €16,300.00 — trading 19.8% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Medical Diagnostics & Research industry median of 5.00. Eurofins-Cerep's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Eurofins-Cerep (XPAR:ALECR), the current Piotroski F-Score is 5 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eurofins-Cerep (XPAR:ALECR) Overvalued in 2026?

Based on GuruFocus' analysis, Eurofins-Cerep stock appears to be undervalued. The current stock price of €16,300.00 is trading 19.8% below its estimated GF Value™ of €20,317.48.

Key valuation signals for XPAR:ALECR:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: €20,317.48 vs. price of €16,300.00 (19.8% below fair value)
  • GF Score™: 27/100 with 4 warning signs
  • Industry Position: 0% at the Medical Diagnostics & Research median (#75 of 208)

No single metric tells the full story. See the XPAR:ALECR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eurofins-Cerep Business Description

Address Le bois l Eveque, Celle l Evescault, FRA, 86600
Eurofins-Cerep SA provides in vitro pharmacology, in vitro ADME-Tox and in vivo PK services and solutions. The company also offers cost-effective drug discovery by identifying at early stages drug candidates and eliminating them. Some solutions provided by the company are - compound management, high-throughout screening, in vitro safety profiling, lead optimization profiling, in vitro ADME profiling, and in vivo PK.
27GF Score

Get the complete analysis for XPAR:ALECR

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16,300.00
Price
€20,317.48
GF Value